21Shares XRP ETF 8-K

What Happened 21Shares US LLC (the Sponsor) filed an 8-K on July 7, 2026, announcing it gave notice on June 30, 2026 to CF Benchmarks Ltd. to terminate the Pricing Benchmark Licensing Agreement effective August 31, 2026. The agreement covered use of the CME CF XRP—Dollar Reference Rate — New York Variant, which CF Benchmarks calculated and administered and which the Trust used to value shares daily and to calculate net asset value (NAV). The Sponsor said the termination is part of a broader transition to a new benchmark provider and expects to enter a licensing agreement with FTSE International Limited on or about August 24, 2026.

Key Details

• Notice to CF Benchmarks provided June 30, 2026; termination effective August 31, 2026.
• Pricing Benchmark: CME CF XRP—Dollar Reference Rate — New York Variant (used to value Trust shares and calculate NAV).
• Sponsor: 21Shares US LLC; Trust: 21Shares XRP ETF (TOXR).
• Planned new provider: FTSE International Limited (license expected on/around Aug 24, 2026); FTSE is unaffiliated and experienced in digital asset indices.
• Both the existing and planned licenses are described as non-exclusive, non-transferable, non-sub-licensable and expected to have one-year initial terms with automatic one-year renewals.

Why It Matters This is an administrative change of the pricing benchmark provider that determines daily valuation and NAV calculation for the 21Shares XRP ETF. Investors should note the provider swap (from CF Benchmarks to FTSE) and the dates involved; the filing does not disclose any change to the Trust’s investment objective or fees. The Sponsor appears to have arranged the new FTSE license to be in place before the CF Benchmarks agreement ends, minimizing disruption to NAV calculations.